FindTrial
Sign In

DISODIUM FOLINATE

DRUG5 trials

Sponsors

Bristol Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company, Charite Universitaetsmedizin Berlin KöR, Universitaetsklinikum Heidelberg AöR

Conditions

Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan without distant metastases.Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)NeoplasmPan tumormetastatic colorectal cancer

Phase 2

Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Bristol-Myers Squibb Services Unlimited CompanyPan tumor
Start: 2020-05-05Target: 307Updated: 2026-01-19
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP)
Not yet recruitingCTIS2025-523055-55-00
Universitaetsklinikum Heidelberg AöRNeoplasm
Target: 100Updated: 2026-09-01

Phase 3

CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Active, not recruitingCTIS2023-503956-29-00
Bristol Myers Squibb International CorporationMicrosatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)
Start: 2019-08-26Target: 571Updated: 2025-12-15
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.
RecruitingCTIS2024-512174-10-00
Charite Universitaetsmedizin Berlin KöRmetastatic colorectal cancer
Start: 2021-11-11Target: 507Updated: 2025-09-04
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multicenter Phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer
RecruitingCTIS2023-508076-11-00
Charite Universitaetsmedizin Berlin KöRColon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan without distant metastases.
Start: 2025-04-01Target: 714Updated: 2025-10-21

Related Papers

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer
BMC Cancer2026-03-20